C2i Genomics
Acquired
Cancer intelligence through AI and whole-genome sequencing
- Headquarters
- New York, New York
- Employees
- 11–50
- Founded
- 2019
- Business Model
- B2B
- Website
- c2i-genomics.com
- Total Funding
- $112.0M
- Last Round
- $100.0M Series BApr 2021
About
C2i Genomics developed a cloud-based cancer intelligence platform that applies artificial intelligence and whole-genome sequencing to liquid biopsy samples to detect minimal residual disease (MRD) in cancer patients. The company's C2-Intelligence Platform analyzes blood samples to provide highly precise cancer detection and treatment monitoring, enabling pharmaceutical and diagnostic organizations to track cancer recurrence and optimize treatment decisions. C2i partnered with AstraZeneca and Premier Inc. before being acquired by Veracyte in February 2024.
Tech Stack
AWS
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account